- Current report filing (8-K)
March 23 2012 - 3:37PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
Date of Report (Date of Earliest event Reported): March 23, 2012
CHINA BIOLOGIC PRODUCTS, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
001-34566
|
75-2308816
|
(State or other jurisdiction of
|
(Commission File No.)
|
(IRS Employer ID No.)
|
incorporation or organization)
|
|
|
18th Floor, Jialong International Building,
19
Chaoyang Park Road
Chaoyang District, Beijing
100125
Peoples Republic of China
(Address of Principal
Executive Offices)
(+86) 10-6598-3111
Registrant's telephone number,
including area code
____________________________________________________________
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (
see
General Instruction A.2. below):
[ ] Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
[ ] Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS;
ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY
ARRANGEMENTS OF CERTAIN OFFICERS.
As previously disclosed, on March 19, 2012, Dr. Tong Jun Lin
resigned as a director of China Biologic Products, Inc. (the "Company"), a member
of the Audit Committee, the Compensation Committee, and the Governance and
Nominating Committee, and as Chairman of the Governance and Nominating
Committee, effective immediately. On the same date, the Companys board of
directors appointed Mr. Yungang Lu, as an
independent director of the Company, a member of the Audit Committee, the
Compensation Committee, and the Governance and Nominating Committee, and as the
Chairman of the Governance and Nominating Committee, effective immediately, to
fill the vacancies resulted from Dr. Lins resignation.
The Company has entered into a Director Agreement and
Indemnification Agreement with Mr. Lu. Under the terms of the Director
Agreement, the Company agreed to pay Mr. Lu a monthly fee of $5,000 as
compensation for his services. Under the terms of the Indemnification Agreement,
the Company agreed to indemnify Mr. Lu against expenses, judgments, fines,
penalties or other amounts actually and reasonably incurred by him in connection
with any proceeding, provided that he has acted in good faith and in the best
interests of the Company. The Company also granted Mr. Lu an option to purchase
20,000 shares of the Companys common stock under the Companys 2008 Equity
Incentive Plan, which options will have an exercise price of $9.16 per share and
will vest in two equal portions on September 20, 2012 and March 20, 2013,
respectively. The description of the terms of the Director Agreement and
Indemnification Agreement herein is qualified by reference to the provisions of
the Director Agreement and Indemnification Agreement attached hereto as Exhibits
10.1
and 10.2, respectively.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date: March 23, 2012
|
CHINA BIOLOGIC PRODUCTS, INC.
|
|
|
|
|
|
|
|
|
By: /s/ Chao Ming Zhao
|
|
|
Chao Ming Zhao
|
|
|
Chief Executive Officer
|
|
EXHIBIT INDEX
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jun 2024 to Jul 2024
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jul 2023 to Jul 2024